Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

Austin, Texas, August 17th, 2026, FinanceWire

• Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, with recruitment completion targeted for the third quarter of 2026 and a PMA process expected to begin by the end of 2027.
• FDA approved a single-arm protocol using a historical microfracture control data package the company owns, and Regentis reports that the first 40 patients closely match that control group.
• In Europe, where GelrinC already holds CE Mark approval, surgeon training began in the third quarter of 2026 at Humanitas Research Hospital in Milan, supported by an expanded clinical site network and a newly approved manufacturing process that raises yield approximately 400%.

For development-stage medical technology companies, regulatory approval and commercial revenue often sit years apart. A trial needs to be finished, a submission must clear review, manufacturing has to scale, surgeons must be trained and distribution has to be built. Companies able to run those workstreams in parallel rather than in sequence compress the distance between clinical validation and market adoption. Regentis Biomaterials (NYSE American: RGNT) is attempting exactly that, advancing its GelrinC(R) cartilage repair platform along a U.S. clinical track and a European commercial track and scaling of manufacturing at the same time.

The U.S. Program Approaches Its Defining Milestone

GelrinC is a cell-free, off-the-shelf hydrogel implant for focal articular cartilage defects in the knee. Rather than harvesting cells from the patient, expanding them in a laboratory and implanting them during a second surgery, GelrinC arrives ready to use and is implanted in a procedure lasting roughly 10 minutes. The hydrogel forms a temporary programmed matrix inside the defect, then…

Read More>>

This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NYSE American: RGNT) as part of a paid investor awareness and marketing engagement.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT

Corporate Communications

IBN

Austin, Texas

www.InvestorBrandNetwork.com

512.354.7000 Office

Editor@InvestorBrandNetwork.com

Contact